Lack of important developments in the European bladder cancer market: F&S

None of the developments in the bladder cancer area have improved the long-term survival rate of patients, with research results also remaining disappointing. Patients still die from muscle invasive disease, despite aggressive therapy with curative intent, according to a new report from market researcher Frost & Sullivan.

Median patient survival after chemotherapy is usually 14 months. Moreover, no new drugs have entered the market over the past two decades, which should encourage the scope for newer and more effective bladder cancer therapeutics.

The new analysis from Frost & Sullivan (http://www.pharma.frost.com), European Bladder Cancer Therapeutics Markets, finds that the sector earned revenues of $128.3 million in 2006 and estimates that this will reach $163.2 million in 2013.